Article Text

other Versions

Download PDFPDF
Intravitreal Bevacizumab Therapy for Neovascular Age Related Macular Degeneration Associated with Poor Initial Visual Acuity
  1. Tural Galbinur (tural001{at},
  2. Edward Averbukh (edwaver{at},
  3. Eyal Banin (banine{at},
  4. Itzhak Hemo (hemoy{at},
  5. Itay Chowers (chowers{at}
  1. Hadassah Medical Center, Israel
  2. Hadassah Medical Center, Israel
  3. Hadassah Medical Center, Israel
  4. Hadassah Medical Center, Israel
  5. Hadassah Medical Center, Israel


    Aim: To assess the efficacy of intravitreal bevacizumab injections for eyes with neovascular age related macular degeneration (NVAMD) and poor initial visual acuity (VA).

    Methods: Retrospective study of 44 consecutive treatment-naïve eyes with NVAMD who had initial VA of 0.1 decimal or worse, and that were treated with intravitreal bevacizumab injections. For the purpose of the study, charts, optical coherence tomography (OCT), and fluorescein angiograms (FA) were reviewed.

    Results: Mean lesion size (SD) was 3375±2116 micron, all lesions showed sub- or intra-retinal fluid in OCT, and active neovascularization composed 41.6±17.7% (range 10-90%) of the lesion area according to FA. Patients received a mean of 2.6±2.42 bevacizumab injections (range: 1-14), and mean VA improved from 1.85±0.64 LogMAR to 1.52±0.77 LogMAR (p = 0.002). At final exam, 9 eyes (20%) had reduced VA, 10 eyes (23%) had stable VA, and 25 eyes (57%) had improved VA compared with baseline, respectively. Following treatment, mean macular thickness reduced from 332±98 micron to 248±79 micron (p < 0.0001).

    Conclusions: Poor initial VA should not refrain from using bevacizumab in eyes with NVAMD. Selection of patients with signs of active neovascularization based on ophthalmoscopy, OCT, and FA may increase the likelihood of favorable response to treatment.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.